We are searching data for your request:
Upon completion, a link will appear to access the found materials.
EU drug agency gives green light for approval of the world's first malaria vaccine
After 30 years of intensive research, the world's first malaria vaccine will soon be approved despite some concerns. The drug, which is developed under the name “RTS, S” but is to be marketed as “Mosquirix”, was developed by the pharmaceutical company GlaxoSmithKline (GSK) together with the PATH Malaria Vaccine Initiative and partly financed by the Bill & Melinda Gates Foundation. In future, babies in malaria risk areas are to be vaccinated with the vaccine.
Some cases of meningitis in children who have received the malaria vaccine
The EU drug agency Ema has approved the approval of the vaccine. Experience has shown that the EU Commission follows Ema's recommendations within one month. RTS, S would be the world's first approved malaria vaccine. According to the World Health Organization (WHO), this year it will be checked when and how the vaccine should be used in the future.
As great as the interest in the vaccine is, it is not a miracle weapon in the fight against malaria. The vaccine has only a limited effect. In 2011 and 2012, studies were published showing that the use of RTS, S reduced malaria cases by six to twelve weeks old babies by about 27 percent and by 5 to 17 months old babies by about 46 percent . According to Ema's recommendation, the vaccine, which is administered in four vaccine doses, should still be used in both age groups. Scientists involved in the development of the vaccine reported that the vaccination was well tolerated by the children. However, there have been isolated cases of meningitis in the vaccinated. However, it is still unclear whether there is a connection to the vaccine.
Malaria vaccine, together with other measures, could significantly reduce the number of malaria deaths
"Even though RTS, S alone is not the answer to malaria, its use, along with the interventions currently available, such as mosquito nets and insecticides, can make a very valuable contribution to combating the effects of malaria on children in African countries where it does is most necessary, ”GSK CEO Andrew Witty is quoted in a message from the pharmaceutical company. "Work does not stop there and GSK will continue to invest in research and development of malaria vaccines and treatments to find more ways to fight this devastating disease."
The use of mosquito nets and insecticides has significantly reduced the number of malaria cases in recent years, but according to the WHO, around 500,000 people still die of the disease every year. Many children were among the dead because only one in five children in Africa are currently receiving malaria medication, the organization says. An effective vaccine could save many lives.
GSK wants to offer the vaccine at an affordable price
The vaccine contains a protein from the malaria pathogen Plasmodium falciparum as well as a potentiator that stimulates the production of antibodies. This is to prevent the parasites from getting into the liver of those affected and driving the disease forward.
GSK announced on Friday that it wanted to keep the price of the vaccine very low. It should only cover the manufacturing costs and generate an additional five percent profit, which will be reinvested in the research of vaccines against malaria or other neglected tropical diseases. (ag)